Nephrotic syndrome: Management of dyslipidemia, pathophysiological insights, and therapeutic perspectives

Mariia Cherska; Olena  Pavlenko; Vira  Zlatkina; Larysa  Kuts; Karina  Taraniuk; Oleksii  Demikhov; Tatyana  Storozhenko; Daniela  Koleva-Tyutyundzhieva; Krystyna  Kukharchuk; Ahmed  El Gohary; Jamol  Uzokov; Iya  Dehtyarova; Krishnaraj Sinhji  Rathod; Nadiia  Demikhova; Yusuf Ziya  Şener

doi:10.31450/ukrjnd.1(89).2026.07

Mariia Cherska State Institution "V. P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine", Kyiv, Ukraine https://orcid.org/0000-0002-3689-2683
Olena Pavlenko State Institution "V. P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine", Kyiv, Ukraine https://orcid.org/0009-0003-8913-6130
Vira Zlatkina V. N. Karazin Kharkiv National University, Kharkiv, Ukraine https://orcid.org/0000-0002-7153-4064
Larysa Kuts Sumy State University, Sumy, Ukraine https://orcid.org/0000-0002-4156-3163
Karina Taraniuk Sumy State University, Sumy, Ukraine https://orcid.org/0000-0002-9315-5540
Oleksii Demikhov Sumy State University, Sumy, Ukraine; Estonian University of Life Sciences, Tartu, Estonia https://orcid.org/0000-0002-9715-9557
Tatyana Storozhenko L.T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine, Kharkiv, Ukraine; Cardiovascular Center Aalst, Aalst, Belgium https://orcid.org/0000-0002-9158-2012
Daniela Koleva-Tyutyundzhieva Medical University of Plovdiv, Plovdiv, Bulgaria https://orcid.org/0000-0002-5973-3503
Krystyna Kukharchuk State Institution "V. P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine", Kyiv, Ukraine; Medical Office “SONOVITA”, Kyiv, Ukraine https://orcid.org/0000-0002-2495-2693
Ahmed El Gohary King Fahd Specialist Hospital, Tabuk, Saudi Arabia https://orcid.org/0000-0002-2102-9318
Jamol Uzokov Republican Specialized Scientific Practical Medical Center of Therapy and Medical Rehabilitation, Tashkent, Uzbekistan https://orcid.org/0000-0003-4452-3391
Iya Dehtyarova Dnipro Institute of Medicine and Public Health, Ukraine https://orcid.org/0000-0002-0807-961X
Krishnaraj Sinhji Rathod Queen Mary University of London, William Harvey Research Institute, Centre for Cardiovascular Medicine and Devices, London, United Kingdom; Barts Interventional Group, Barts Heart Centre, St. Bartholomew's Hospital, London, United Kingdom https://orcid.org/0000-0003-4268-5055
Nadiia Demikhova Sumy State University, Sumy, Ukraine; Tallinn University of Technology, Tallinn, Estonia https://orcid.org/0000-0003-4139-1645
Yusuf Ziya Şener Yavuzeli State Hospital, Gaziantep, Turkey https://orcid.org/0000-0001-5151-5133

DOI: https://doi.org/10.31450/ukrjnd.1(89).2026.07

Keywords: nephrotic syndrome, dyslipidemia, hypoalbuminemia, glomerulosclerosis, chronic kidney disease, oxidative stress, atherosclerosis, chronic heart failure, hypolipidemic drugs.

Abstract

Dyslipidemia is a characteristic feature of nephrotic syndrome (NS), which significantly increases the risk of cardiovascular complications and progression of chronic kidney disease. This review analyzes current understanding of the complex pathophysiological mechanisms of lipid metabolism disorders in NS. Particular attention is paid to the impact of proteinuria on the synthesis of lipoproteins by the liver and impaired clearance. The article systematizes current therapeutic strategies. Therapeutic prospects aimed at correcting the lipid profile as a means of nephroprotection are considered. The review emphasizes the need for a personalized approach to the management of dyslipidemia, taking into account the etiology of NS and the functional state of the kidneys.

Downloads

Download data is not yet available.

References

Ponticelli C, Arnaboldi L, Moroni G, Fornoni A. How We Treat Dyslipidemia in Prolonged Nephrotic Syndrome. Clin J Am Soc Nephrol. 2024;19(10):1327-29. doi: 10.2215/CJN.0000000000000514.

Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int. 2016;90(1):41-52. doi: 10.1016/j.kint.2016.02.026.

Kronenberg F. Dyslipidemia and nephrotic syndrome: recent advances. J Ren Nutr.2005;15(2):195-203. doi: 10.1053/j.jrn.2004.10.003.

Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol. 2018;14(1):57-70. doi: 10.1038/nrneph.2017.155.

Baek HS. Mechanism, clinical consequences, and management of dyslipidemia in children with nephrotic syndrome. Child Kidney Dis. 2022;26(1):25-30. doi: 10.3339/ckd.22.020.

Young SG, Davies BS, Fong LG, Gin P, Weinstein MM, Bensadoun A, et al. GPIHBP1: an endothelial cell molecule important for the lipolytic processing of chylomicrons. Curr Opin Lipidol. 2007;18(4):389-96. doi: 10.1097/MOL.0b013e3281527914.

Wang L, Shearer GC, Budamagunta MS, Voss JC, Molfino A, Kaysen GA. Proteinuria decreases tissue lipoprotein receptor levels resulting in altered lipoprotein structure and increasing lipid levels. Kidney Int. 2012;82(9):990-999. doi: 10.1038/ki.2012.244.

Morris AW. Nephrotic syndrome: PCSK9: a target for hypercholesterolaemia in nephrotic syndrome. Nat Rev Nephrol. 2016;12(9):510. doi: 10.1038/nrneph.2016.111.

Zhou Y, Zhang X, Chen L, Wu J, Dang H, Wei M, et al. Expression profiling of hepatic genes associated with lipid metabolism in nephrotic rats. Am J Physiol Renal Physiol. 2008;295(3):F662-F671. doi: 10.1152/ajprenal.00046.2008.

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021.

Alqudsi M, Alhumaid S, Almagooshi AS, Samman AM, Alqaraishi AM. Characteristics of Dyslipidemia in Primary Nephrotic Syndromes. Cureus. 2025;17(5):e84077. doi: 10.7759/cureus.84077.

Chernatska O, Grek A. COVID-19 and chronic kidney disease: peculiarities of treatment. Ukr J Nephr Dial.2022;2(74):83-89. doi: 10.31450/ukrjnd.2(74).2022.11.

Das H, Satapathy A, John J, Kar M, Mohakud S. Endothelial Dysfunction in Children With Nephrotic Syndrome: A Cross-Sectional Study. Cureus. 2024;16(2):e53628. doi: 10.7759/cureus.53628.

Chernatska OM, Prystupa LN, Fadieieva HA, Liashenko AV, Smiianova YO. Arterial hypertension associated with hyperuricemia: features of heart damage. Wiad Lek. 2020;73(5):943-946. doi: 10.36740/WLek202005119.

Prykhodko OO, Hula VI, Yarmolenko OS, Pernakov MS, Sulim LG, Bumeister VI, et al. Microscopic changes in rat organs under conditions of total dehydration. Azerbaijan Medical Journal. 2016;4:95-100.

Verma R, Deepthi B, Saha A, Bhattacharjee J. Endothelial Dysfunction in Children with Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome. Indian J Nephrol. 2025;35(4):480-84. doi: 10.25259/ijn_568_23.

Pei K, Gui T, Li C, Zhang Q, Feng H, Li Y, et al. Recent Progress on Lipid Intake and Chronic Kidney Disease. Biomed Res Int.2020:2020:3680397. doi: 10.1155/2020/3680397.

Demikhova N, Kuts L, Bokova S, Vlasenko O, Merisalu E. Diagnostic and therapeutic potential of interleukin-37 in kidney diseases: A mini-review. Ukr J Nephrol Dialys. 2025; 2(86): 90-97. doi: 10.31450/ukrjnd.2(86).2025.09.

Stepanova N. Dyslipidemia in Peritoneal Dialysis: Implications for Peritoneal Membrane Function and Patient Outcomes. Biomedicines. 2024;12(10):2377. doi: 10.3390/biomedicines12102377.

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J.2020;41(1):111-188. doi: 10.1093/eurheartj/ehz455.

https://academic.oup.com/eurheartj/article/46/42/4359/8234482?login=false">Mach F, Koskinas KC, Roeters van Lennep JE, Tokgözoğlu L, Badimon L, Baigent C, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359-78. doi: 10.1093/eurheartj/ehaf190.

https://www.ahajournals.org/doi/10.1161/CIR.0000000000000624">Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/ NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1046-e1081. doi: 10.1161/CIR.0000000000000624.

https://www.kidney-international.org/article/S0085-2538(15)56385-0/fulltext">Wanner C, Tonelli M, Members KDIGOLGDWG. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85(6):1303-9. doi:10.1038/ki.2014.31.

Politano SA, Colbert GB, Hamiduzzaman N. Nephrotic Syndrome. Prim Care. 2020;47(4):597-613. doi: 10.1016/j.pop.2020.08.002.

Krakowska-Jura K, Kler AN, Wajerowska W, Konieczny A, Banasik M. Prognostic Factors of Proteinuria Remission in Primary Membranous Nephropathy. J Clin Med. 2025;14(9):2880. doi: 10.3390/jcm14092880.

Floege J, Gibson KL, Vivarelli M, Liew A, Radhakrishnan J, Rovin BH, et al. KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children. Kidney Int. 2025;107(5S):S241-S289. doi: 10.1016/j.kint.2024.11.007.

Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies, with the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2021;42(34):3227–3337. doi: 10.1093/eurheartj/ehab484.